Table 2.
Prevalence of liver dysfunction prior to cART
| Liver threshold/biomarker | na/nb or median (IQR) | % | |
|---|---|---|---|
| ALT≥1*ULN | 685/1930 | 35.49% | |
| ALT≥3*ULN | 111/1930 | 5.75% | |
| ALT≥5*ULN | 36/1930 | 1.87% | |
| ALT≥8*ULN | 16/1930 | 0.83% | |
| ALT≥3*ULN & Total Bilirubin≥2*ULN | 0/403 | 0.00% | |
| ALP≥3*ULN | 3/398 | 0.75% | |
| TBIL≥2*ULN | 7/403 | 1.74% | |
| AST/ALT ratio>0.7 | 1199/1226 | 97.80% | |
| AST/ALT ratio>1.0 | 1098/1226 | 89.56% | |
| Median (IQR) AST/ALT ratio | 1.51 (1.18–2.13) | ||
| APRI >0.5 | 322/988 | 32.59% | |
| APRI >1.5 | 84/988 | 8.50% | |
| Median (IQR) APRI score | 0.34 (0.18–0.63) | ||
| FIB4 index >1.3 | 28/988 | 2.83% | |
| Median (IQR) FIB4 index | 0.14 (0.06–0.25) | ||
a
Number of children with threshold enzyme elevations.
b
Total number of children with the laboratory tests obtained at baseline.
cART- combination antiretroviral therapy; IQR-interquartile range; ULN-upper limit of normal; ALT-alanine aminotransferase; AST-aspartate aminotransferase; ALP-alkaline phosphatase; TBIL-total bilirubin; APRI: AST to Platelet Ratio Index calculated from ([AST/upper limit of normal]/platelet count [109/l]) × 100; FIB4 index: calculated from age × AST level/platelet count ×√ALT.